 SAN FRANCISCO, Aug. 25, 2021 GLOBE NEWSWIRE -- FibroGen, Inc. NASDAQ: FGEN today announced positive topline results from WHITNEY, the Companys Phase 2 clinical study of roxadustat, a first-in-class oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor HIF-PHI, for the treatment of chemotherapy-induced anemia CIA. 